On a CT scan, mesothelioma most commonly appears as thickening of the pleura, the thin membrane that lines the lungs and chest wall. This pleural thickening shows up in 90% to 92% of patients and is the single most recognizable feature of the disease. The thickening can be smooth, nodular, or lumpy, and it often wraps partially or fully around the lung on the affected side.
The Primary CT Finding: Pleural Thickening
Healthy pleura is so thin it’s barely visible on a CT scan. When mesothelioma develops, the pleura becomes abnormally thick, and this thickening takes on characteristic patterns that radiologists look for. The features most strongly suggestive of mesothelioma include nodular or lobulated (bumpy, irregular) thickening, thickening along the mediastinal pleura (the portion lining the center of the chest near the heart and major blood vessels), and parietal pleural thickening greater than 1 cm.
Circumferential thickening, where the abnormal tissue wraps all the way around the lung like a rind, is a hallmark of more advanced disease. At this stage, the affected lung often appears shrunken because the tumor constricts it, pulling the chest wall inward on that side. Thickening that extends along the fissures (the natural dividing lines between the lobes of the lung) is another sign radiologists flag as suspicious.
Pleural thickness also carries prognostic meaning. Research into staging has identified 5.1 mm as a significant threshold: patients whose maximum pleural thickness stayed below 5.1 mm had a median survival of about 24 months, compared to roughly 18 months when thickness exceeded that mark.
How It Differs From Benign Pleural Disease
Asbestos exposure can cause benign pleural plaques, which are the most common radiological sign of past asbestos contact. These plaques tend to be focal, meaning they appear in isolated patches rather than spreading along large stretches of the pleura. Mesothelioma, by contrast, is far more likely to produce diffuse and circumferential thickening that covers a broad area.
Several CT features help distinguish malignant from benign pleural disease. Nodular thickening has a specificity of 96%, meaning that when bumpy, irregular pleural thickening is present, it very rarely turns out to be benign. Rind-like encasement of the lung has a specificity of 95%. Mediastinal pleural involvement has a sensitivity of 70%, making it one of the more reliably detected signs of malignancy. Pleural thickness over 1 cm, while less sensitive on its own (47%), is still a strong indicator when combined with other findings. The average thickest measurement in mesothelioma patients is around 17 mm, compared to about 10 mm in patients with other malignant pleural diseases like metastatic cancer.
When mesothelioma is compared specifically to metastatic cancer that has spread to the pleura from elsewhere, a few additional clues emerge. Mesothelioma tends to enhance (brighten) homogeneously on contrast-enhanced scans, while metastatic pleural disease more often shows patchy, uneven enhancement. Mesothelioma also involves the diaphragmatic pleura (the lining over the diaphragm) about 65% of the time, compared to 38% for metastatic disease, and is far more likely to form pleural masses.
Pleural Effusion and Other Secondary Signs
A pleural effusion, a buildup of fluid in the space between the lung and the chest wall, is frequently the first thing that brings a patient to imaging. On a CT scan, this fluid appears as a gray or white collection pooling at the base of the chest cavity. In mesothelioma, effusions can be large and are often accompanied by the characteristic pleural thickening described above. Sometimes, however, the effusion is so large it obscures the underlying thickening, and a follow-up scan after fluid drainage may be needed to see the pleura clearly.
Enlarged lymph nodes in the mediastinum (the central chest area) can also appear on CT and suggest the disease has begun to spread. In advanced cases, the scan may show tumor extending into the chest wall soft tissues, the pericardium (the sac around the heart), or even through the diaphragm into the abdomen.
Why Contrast Matters
Mesothelioma imaging is best performed with intravenous contrast dye, which is injected before the scan. The contrast causes the tumor tissue to brighten on the images, making it far easier to detect and measure pleural deposits that might otherwise blend with surrounding tissue. British Thoracic Society guidelines recommend contrast-enhanced CT optimized for pleural evaluation as the first cross-sectional imaging study for anyone with suspected mesothelioma. A plain, non-contrast CT can miss subtle disease.
Peritoneal Mesothelioma on CT
About 10% to 15% of mesothelioma cases develop in the peritoneum, the membrane lining the abdomen, rather than the chest. On CT, peritoneal mesothelioma looks quite different from its pleural counterpart but follows a similar logic of membrane thickening and fluid accumulation.
Radiologists classify what they see into two broad patterns. The “wet” type shows large-volume ascites (abdominal fluid), omental caking (a thickened, matted appearance of the fatty apron that drapes over the intestines), and diffuse plaque-like thickening of the peritoneal lining. The “dry” type presents with solid peritoneal masses and less fluid. The more aggressive sarcomatoid subtype tends to form large, distinct masses that may be localized or scattered throughout the abdomen, while the more common epithelioid subtype typically shows ascites, omental thickening, and small mesenteric nodules.
What CT Cannot Do Alone
CT is the workhorse of mesothelioma imaging, but it has clear limits. It cannot confirm the diagnosis by itself. A tissue biopsy is always needed to verify that abnormal pleural thickening is mesothelioma rather than another malignancy or, less commonly, a benign process. CT also struggles to accurately assess certain details that affect treatment planning, like whether tumor has invaded the chest wall muscle or the diaphragm at a microscopic level.
For patients where the exact depth of invasion would change the treatment approach, MRI provides better soft-tissue contrast and can help clarify what CT leaves ambiguous. PET-CT, which combines anatomical imaging with a metabolic tracer that highlights active cancer cells, is used when checking for distant spread to other organs. PET-CT results should be interpreted cautiously in patients who have previously had talc pleurodesis (a procedure to seal the pleural space), because the talc itself can light up on PET and mimic cancer activity.